

594~598.CD137单抗联合IL-15体外扩增NK细胞及其对肺癌细胞的杀伤活性[J].陶家龙,邱玉华,庄志祥,沈丽琴.中国肿瘤生物治疗杂志,2012,19(6)

CD137单抗联合IL-15体外扩增NK细胞及其对肺癌细胞的杀伤活性 [点此下载全文](#)

[陶家龙](#) [邱玉华](#) [庄志祥](#) [沈丽琴](#)

苏州大学附属第二医院 肿瘤科, 江苏 苏州 215004; 苏州大学 免疫学教研室, 江苏 苏州 215123; 苏州大学附属第二医院 肿瘤科, 江苏 苏州 215004; 苏州大学附属第二医院 肿瘤科, 江苏 苏州 215004

基金项目: 苏州市科技基金项目资助 (No.510307)

DOI: 10.3872/j.issn.1007-385X.2012.6.005

摘要:

目的: 建立CD137单抗联合IL-15体外扩增NK细胞的方案, 研究扩增后NK细胞对肺癌细胞的杀伤活性。方法: 分离健康人外周血单个核细胞, 经免疫磁珠阴性分选获取CD3⁻CD56⁺NK细胞, 将NK细胞分成对照组、IL-2组、IL-2+CD137单抗组、IL-2+IL-15组、IL-2+CD137单抗+IL-15组进行培养, 经锥虫蓝染色法计算NK细胞的扩增倍数, 流式细胞术检测NK细胞的表型, LDH酶释放法检测NK细胞对肺癌细胞株A549的杀伤活性, ELISA法检测扩增后NK细胞培养液上清中IFN-γ的分泌量。结果: 经磁珠分选后NK细胞纯度为(93.28±3.21)%。IL-2+CD137单抗+IL-15组NK细胞扩增倍数明显高于IL-2+CD137单抗组、IL-2+IL-15组、IL-2组及对照组[(86.20±5.00) vs (60.01±5.00)、(49.06±4.39)、(17.04±1.49)、(3.95±0.23)倍, P<0.01]。IL-2+CD137单抗+IL-15组NK细胞对A549细胞的杀伤效率明显高于其他各组[(93.14±3.27)% vs (83.15±4.03)%、(71.25±3.24)%、(62.27±3.01)%、(49.38±2.35)%, P<0.01]。IL-2+CD137单抗+IL-15组培养液上清中的IFN-γ的分泌水平明显高于IL-2+CD137单抗组、IL-2+IL-15组、IL-2组及对照组[(296.25±9.79) vs (260.47±11.55)、(201.13±6.36)、(138.36±6.09)、(38.42±3.56) pg/ml, P<0.01]。结论: CD137单抗联合IL-15能高效扩增NK细胞, 扩增的NK细胞高效杀伤A549肺癌细胞。

关键词: [NK细胞](#) [CD137单抗](#) [IL-15](#) [IFN-γ](#) [肺癌细胞](#)

In vitro expansion of NK cells by combination of CD137 monoclonal antibody and IL-15 and their cytotoxicity against lung cancer cells [Download Fulltext](#)

[TAO Jia-long](#) [QIU Yu-hua](#) [ZHUANG Zhi-xiang](#) [SHEN Li-qin](#)

Department of Oncology, Second Hospital Affiliated to Soochow University, Suzhou 215004, Jiangsu, China; Department of Immunology, Soochow University, Suzhou 215123, Jiangsu, China; Department of Oncology, Second Hospital Affiliated to Soochow University, Suzhou 215004, Jiangsu, China; Department of Oncology, Second Hospital Affiliated to Soochow University, Suzhou 215004, Jiangsu, China

Fund Project: Project supported by the Science and Technology Foundation of Suzhou (No. 510307)

Abstract:

Objective: To explore an in vitro expansion method of NK cells by CD137 monoclonal antibody combination with IL-15, and to study the cytotoxicity of expanded NK cells against lung cancer cells. Methods: CD3⁻CD56⁺NK cells were isolated from peripheral blood mononuclear cells (PBMCs) using negative MACS, and divided into five groups: a control group, IL-2, IL-2+CD137mAb, IL-2+IL-15, and IL-2+IL-15+CD137mAb groups. The expansion, phenotype and cytotoxicity of lung cancer A549 cells and IFN-γ secretion of NK cells were evaluated by MTT, FACS, LDH, and ELISA, respectively. Results: The purity of NK cells increased to (93.28±3.21)% after MACS sorting. In group IL-2+IL-15+CD137mAb, the NK cells were expanded obviously higher than were those in IL-2+CD137mAb, IL-2+IL-15, IL-2 and control groups (86.20±5.00 vs 60.01±5.00, 49.06±4.39, 17.04±1.49, 3.95±0.23, P<0.01). The cytotoxicity of expanded NK cells in group IL-2+IL-15+CD137mAb was significantly higher than that in the other groups ([93.14±3.27]% vs [83.15±4.03]%, [7125±3.24]%, [62.27±3.01]%, [49.38±2.35]%, P<0.01). In group IL-2+IL-15+CD137mAb, the IFN-γ level in cell supernatant was significantly higher than that in IL-2+CD137mAb, IL-2+IL-15, IL-2 and control groups ([296.25±9.79] vs [260.47±11.55], [201.13±6.36], [138.36±6.09], [38.42±3.56] pg/ml; P<0.01). Conclusion: CD137 monoclonal antibody combination with IL-15 can efficiently expand NK cells with an effective cytotoxicity on lung cancer A549 cells.

Keywords: [natural killer cell](#) [CD137mAb](#) [IL-15](#) [IFN-γ](#) [lung cancer cell](#)

[查看全文](#) [查看/发表评论](#) [下载PDF阅读器](#)